{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:09:12Z","timestamp":1775628552330,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with severe asthma have new therapeutic opportunities with biologic agents, reducing exacerbation rates, symptom scores, and oral corticosteroid use; however, their effects on lung function appear to be variable. The aim of this study is to evaluate the clinical and inflammatory outcomes of biologic therapy in patients with severe asthma, stratified according to baseline bronchial inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective observational study in patients with severe asthma at 6 and 12 months after initiation of biologic therapy. Patients were categorized according to their baseline airway inflammatory profile. The inflammatory biomarkers evaluated included induced sputum, fractional exhaled nitric oxide (FeNO), and peripheral blood leukocyte counts. Lung function, comorbidities, exacerbation rate, and asthma control (assessed by ACQ-6 and ACT) were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 113 patients with severe asthma were analyzed. Patients with a paucigranulocytic pattern were excluded from further analyses due to their small number (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910). Among the remaining subjects (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009103), 62.8% exhibited an eosinophilic pattern, 13.3% a mixed granulocytic pattern, and 15.0% a neutrophilic pattern. Most neutrophilic patients (82.7%) presented elevated type 2 (T2) biomarkers (FeNO and\/or blood eosinophils). Differences in baseline biomarkers and comorbidities reflected the underlying airway inflammatory patterns; forced vital capacity (FVC, L) was lower in neutrophilic patients compared with the other groups. Neutrophilic patients had higher frequencies of obstructive sleep apnea and lower chronic rhinosinusitis with nasal polyps than eosinophilic subjects. During follow-up, all patients showed a significant reduction in their ability to produce sputum (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), as well as significant decreases in exacerbation rate and symptom burden. Eosinophilic and mixed granulocytic patients exhibited significant improvements in lung function, whereas neutrophilic patients did not. Only eosinophilic patients showed a significant reduction in airway inflammation. Oral corticosteroid doses decreased across all groups, but significantly only in eosinophilic patients. Clinical and inflammatory improvements were observed after 6 months of biologic therapy, with no further significant changes at 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After 12 months of biologic therapy, patients showed phenotype-dependent responses, with neutrophilic patients demonstrating smaller clinical and inflammatory improvements compared with those with eosinophilic or mixed granulocytic phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1789783","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:32:18Z","timestamp":1775626338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of sputum neutrophilia on the efficacy of biologics in severe asthma"],"prefix":"10.3389","volume":"7","author":[{"given":"Patrizia","family":"Pignatti","sequence":"first","affiliation":[{"name":"Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri IRCCS","place":["Pavia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Zappa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS","place":["Tradate, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ardesi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS","place":["Tradate, Italy"]},{"name":"Department of Medicine and Surgery, University of Insubria","place":["Varese, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Vanetti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS","place":["Tradate, Italy"]},{"name":"Department of Medicine and Surgery, University of Insubria","place":["Varese, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Centis","sequence":"additional","affiliation":[{"name":"Servizio di Epidemiologia e Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS","place":["Tradate, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS","place":["Tradate, Italy"]},{"name":"Department of Medicine and Surgery, University of Insubria","place":["Varese, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Visca","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS","place":["Tradate, Italy"]},{"name":"Department of Medicine and Surgery, University of Insubria","place":["Varese, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"B1","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1164\/rccm.202310-1730OC","article-title":"Biomarker predictors of clinical efficacy of the anti-IgE biologic omalizumab in severe asthma in adults: results of the SoMOSA study","volume":"210","author":"Djukanovi\u0107","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12890-025-04044-7","article-title":"Clinical outcomes after switching from omalizumab to anti-IL-5\/IL-5R biologics in severe asthma: a retrospective cohort study","volume":"26","author":"Akku\u015f","year":"2025","journal-title":"BMC Pulm Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/all.70031","article-title":"Predictors of response to biologics for severe asthma: a systematic review and meta-analysis","volume":"81","author":"Rattu","year":"2026","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1159\/000527125","article-title":"Analysis of patients with asthma and mixed granulocytic inflammatory pattern in sputum","volume":"101","author":"Pignatti","year":"2022","journal-title":"Respiration"},{"key":"B9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma","volume":"22","year":"2003","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1183\/09031936.02.00000302","article-title":"Sputum induction","volume":"20","author":"Paggiaro","year":"2002","journal-title":"Eur Respir J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1183\/09031936.02.00104002","article-title":"Induced sputum: time from expectoration to processing","volume":"19","author":"Efthimiadis","year":"2002","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1016\/j.jaip.2020.05.053","article-title":"New perspectives on difficult asthma; sex and age of asthma-onset based phenotypes","volume":"8","author":"Azim","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.rmed.2005.08.012","article-title":"Identifying \u2018well-controlled\u2019 and \u2018not well-controlled\u2019 asthma using the asthma control questionnaire","volume":"100","author":"Juniper","year":"2006","journal-title":"Respir Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the asthma control test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1183\/20734735.012717","article-title":"The global lung function initiative (GLI) network: bringing the world's Respiratory reference values together","volume":"13","author":"Cooper","year":"2017","journal-title":"Breathe"},{"key":"B19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1055\/a-2102-8128","article-title":"Criteria for evaluation of response to biologics in severe asthma\u2014the biologics asthma response score (BARS)","volume":"79","author":"Milger","year":"2025","journal-title":"Pneumologie"},{"key":"B21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2147\/JAA.S517784","article-title":"Secondary non-response to biologic treatment in patients with severe asthma","volume":"18","author":"Mobayed","year":"2025","journal-title":"J Asthma Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaci.2020.04.018","article-title":"Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months","volume":"147","author":"Abdel-Aziz","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2025.05.031","article-title":"Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma","volume":"156","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaci.2019.03.013","article-title":"Stratification of asthma phenotypes by airway proteomic signatures","volume":"144","author":"Schofield","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"107881","DOI":"10.1016\/j.rmed.2024.107881","article-title":"Factors associated with uncontrolled severe asthma in the biologic era","volume":"236","author":"Yasui","year":"2025","journal-title":"Respir Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jaip.2025.04.055","article-title":"Diagnosis and treatment options for T2-low asthma","volume":"13","author":"Thomas","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2020.01.007","article-title":"The role of lung and gut Microbiota in the pathology of asthma","volume":"52","author":"Barcik","year":"2020","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"00616-2024","DOI":"10.1183\/23120541.00616-2024","article-title":"Neutrophilic inflammation in sputum or blood does not define a clinically distinct asthma phenotype in ATLANTIS","volume":"11","author":"Kuks","year":"2025","journal-title":"ERJ Open Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/thorax-2022-219781","article-title":"Super-responders to anti-IL-5\/anti-IL-5R are characterised by high sputum eosinophil counts at baseline","volume":"78","author":"Gerday","year":"2023","journal-title":"Thorax"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108151","DOI":"10.1016\/j.rmed.2025.108151","article-title":"High local type-2 inflammation is linked to response in severe asthma treated with anti-interleukin-5 receptor","volume":"243","author":"Moermans","year":"2025","journal-title":"Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1691886","DOI":"10.3389\/falgy.2025.1691886","article-title":"Impact of biologic therapy on blood cell indices and exacerbation risk in severe asthma: predictive value of the neutrophil-to-eosinophil ratio","volume":"6","author":"Al-Ahmad","year":"2025","journal-title":"Front Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1789783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:32:19Z","timestamp":1775626339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1789783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":32,"alternative-id":["10.3389\/falgy.2026.1789783"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1789783","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"1789783"}}